Hosted on MSN
Cellectar (CLRB) phase 2b data shows durable responses in Waldenström macroglobulinemia
Cellectar Biosciences, Inc. (NASDAQ:CLRB) reported updated Phase 2b data from its CLOVER WaM study, showing durable responses for iopofosine I 131 in relapsed or refractory Waldenström ...
Opthea Limited has announced the publication of Phase 2b data on sozinibercept, a novel combination therapy for treating wet age-related macular degeneration (wet AMD), in the journal Ophthalmic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results